Kura Oncology FY2025 EPS Cut by Brookline Capital Management

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for shares of Kura Oncology in a research report issued to clients and investors on Monday, January 5th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($2.87) for the year, down from their prior estimate of ($2.74). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Brookline Capital Management also issued estimates for Kura Oncology’s Q4 2025 earnings at ($0.61) EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at $0.32 EPS, FY2028 earnings at $3.62 EPS and FY2029 earnings at $11.72 EPS.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million.

A number of other equities analysts have also commented on KURA. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Kura Oncology in a research note on Friday, November 14th. Wedbush restated an “outperform” rating and issued a $38.00 target price (up previously from $36.00) on shares of Kura Oncology in a report on Friday, November 14th. Barclays reaffirmed an “overweight” rating and issued a $28.00 target price (up previously from $11.00) on shares of Kura Oncology in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Finally, Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.57.

Kura Oncology Stock Performance

Kura Oncology stock opened at $9.54 on Wednesday. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $12.49. The firm’s 50 day simple moving average is $10.76 and its 200-day simple moving average is $8.73. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. The company has a market cap of $830.17 million, a P/E ratio of -3.85 and a beta of 0.25.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its position in Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after acquiring an additional 3,072 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Kura Oncology by 127.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares during the last quarter. State of Wyoming acquired a new stake in shares of Kura Oncology in the 1st quarter valued at $48,000. Merit Financial Group LLC bought a new stake in Kura Oncology in the third quarter worth $89,000. Finally, Jain Global LLC acquired a new position in Kura Oncology during the third quarter worth $91,000.

Insider Activity

In other news, COO Kathleen Ford sold 6,902 shares of Kura Oncology stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $77,164.36. Following the completion of the sale, the chief operating officer directly owned 105,373 shares in the company, valued at $1,178,070.14. The trade was a 6.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Francis Burrows sold 23,726 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $9.78, for a total value of $232,040.28. Following the completion of the sale, the insider directly owned 33,735 shares of the company’s stock, valued at approximately $329,928.30. The trade was a 41.29% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 68,343 shares of company stock valued at $730,858. 6.40% of the stock is currently owned by company insiders.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.